<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782351</url>
  </required_header>
  <id_info>
    <org_study_id>XYFY2016-KL002-01</org_study_id>
    <nct_id>NCT02782351</nct_id>
  </id_info>
  <brief_title>Humanized CAR-T Therapy for Treatment of B Cell Malignancy</brief_title>
  <official_title>Humanized CAR-T Therapy for Treatment of Recurrent or Refractory B Cell Malignancy by Targeting CD19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kai Lin Xu; Jun Nian Zheng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iCarTAB BioMed Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huaian first people's hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study evaluates the safety and efficacy of humanized Chimeric antigen receptor T
      cells (CAR-T) in treating recurrent or refractory B cell malignancy targeting CD19 with a
      humanized scFv. All participants will receive autologous chimeric antigen receptor engineered
      T cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD19 has been extensively evaluated as a therapeutic target for recurrent or refractory B
      cell malignancy by chimeric antigen receptor T cell therapy, the single chain antibody
      sequence (scFv) against CD19 derived from a mouse hybridoma was widely employed. However, the
      immunogenicity of the mouse scFv sequence might be one of the reasons that CAR-T cells cannot
      persist in vivo for long. In present study investigators replace the mouse-derived scFv with
      a a humanized one and evaluate its safety and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAR-T cells persistence in peripheral blood</measure>
    <time_frame>12 months</time_frame>
    <description>The presence of CAR T cells in patients' peripheral blood will be quantified with real time qPCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>B cell number and immunoglobulins in peripheral blood</measure>
    <time_frame>12 months</time_frame>
    <description>The number of B cells and immunoglobulins in peripheral blood will be evaluated by routine methods</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In interventional studies, patients enrolled will receive autologous 2nd generation CAR-T cells, which contain a humanized single chain antibody sequence against CD19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T</intervention_name>
    <description>Patients will be infused with autologous CAR-T infusion in a dose escalating manner.</description>
    <arm_group_label>CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ageâ‰¥3 at the time of consent

          -  Survival time&gt;12 weeks

          -  B cell hematological malignancies by pathological examination

          -  Chemotherapy failure or recurrent B cell malignancy

          -  Creatinine&lt; 2.5mg/dl

          -  Glutamic-pyruvic transaminase, glutamic oxalacetic transaminase&lt; 3 fold of normal
             level

          -  Karnofsky Performance Status&gt;50% at the time of screening

          -  Bilirubin&lt;2.0mg/dl

          -  Adequate pulmonary, renal, hepatic, and cardiac function

          -  Fail in autologous or allogenic haemopoietic stem cell transplantation

          -  Free of leukocytes removal contraindications

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV)
             infection at the time of screening

          -  Previous treatment with any gene therapy product

          -  Abnormal vital signs

          -  Highly allergic constitution or history of severe allergies, especially allergy to
             interleukin-2

          -  General infection or local severe infection, or other infection that is not controlled

          -  Dysfunction in lung, heart, kidney and brain.

          -  Severe autoimmune diseases

          -  other symptoms that are not applicable for CAR-T
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KaiLin Xu, MD. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Cao, M.D., Ph.D.</last_name>
    <phone>8651685802291</phone>
    <email>zimu05067@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JunNian Zheng, M.D., Ph.D.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huaian First People's Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunling Wang, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated hospital of Xuzhou medical college</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Cao, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015 Jul;14(7):499-509. doi: 10.1038/nrd4597. Review.</citation>
    <PMID>26129802</PMID>
  </reference>
  <results_reference>
    <citation>Davila ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, Brentjens R. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol. 2014 Apr;99(4):361-71. doi: 10.1007/s12185-013-1479-5. Epub 2013 Dec 6. Review.</citation>
    <PMID>24311149</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xuzhou Medical University</investigator_affiliation>
    <investigator_full_name>Kai Lin Xu; Jun Nian Zheng</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

